Skip to main content
main-content

27.02.2019 | Original Article – Clinical Oncology

Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma

Zeitschrift:
Journal of Cancer Research and Clinical Oncology
Autoren:
Xingyu Cheng, Han Yin, Juan Fu, Chunya Chen, Jianhong An, Jiexia Guan, Rong Duan, Hengming Li, Hong Shen
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00432-019-02861-y) contains supplementary material, which is available to authorized users.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose

Lung cancer prevalence with its high mortality rate is a trending topic globally. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The human gene TTN encoding for TITIN protein is known as major mutation gene in many types of tumor including NSCLC. However, it is still controversial that TTN is a cancer-associated candidate considering tumor heterogeneity and complex genetic structure. In-depth researches on correlation between TTN mutation and NSCLC are still limited and discussable.

Methods

Related somatic mutation profiles and attached clinical data were from The Cancer Genome Atlas (TCGA) lung project. Clinical relevance analysis of TTN mutation was evaluated using univariate analysis and a binary logistic regressive model. Survival analysis and screening of independent prognostic factors in mutation types were conducted by Cox proportional hazards models and Kaplan–Meier methods.

Results

Available data covering lung adenocarcinoma (n = 517) and lung squamous cell carcinoma (n = 492) were analyzed. TTN genetic mutations exhibited significant association with lung squamous cell carcinoma. Patients with lung squamous cell carcinoma possessed favorable overall survival benefits from TTN mutant type and both favorable overall survival and disease-free survival benefits from TTN/TP53 double mutation. For patients with lung squamous cell carcinoma, about 85% of subjects with TTN mutation harbored missense variations, which was an independent indicator of good prognosis.

Conclusions

Missense mutation of TTN may act as a beneficial role in lung squamous cell carcinoma, but not in lung adenocarcinoma.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (XLSX 15 KB)
432_2019_2861_MOESM1_ESM.xlsx
Supplementary material 2 (XLSX 15 KB)
432_2019_2861_MOESM2_ESM.xlsx
Supplementary material 3 (XLSX 15 KB)
432_2019_2861_MOESM3_ESM.xlsx
Supplementary material 4 (XLSX 13 KB)
432_2019_2861_MOESM4_ESM.xlsx
Supplementary material 5 (XLSX 13 KB)
432_2019_2861_MOESM5_ESM.xlsx
Supplementary material 6 (XLSX 12 KB)
432_2019_2861_MOESM6_ESM.xlsx
Supplementary material 7 (XLSX 12 KB)
432_2019_2861_MOESM7_ESM.xlsx
Supplementary material 8 (XLSX 13 KB)
432_2019_2861_MOESM8_ESM.xlsx
Supplementary material 9 (XLSX 13 KB)
432_2019_2861_MOESM9_ESM.xlsx
Supplementary material 10 (XLSX 13 KB)
432_2019_2861_MOESM10_ESM.xlsx
Supplementary material 11 (XLSX 13 KB)
432_2019_2861_MOESM11_ESM.xlsx
Literatur
Über diesen Artikel
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise